#United States #CVS Health #Woonsocket #Aetna #Health Services

Overview of CVS Health's Third Quarter Results

CVS Health Corporation has recently shared its operational results for the three months concluding on September 30, 2026. The report indicates a significant year-over-year revenue increase of 5.4%, reaching a total of $108.4 billion. This growth is attributed to strong performances across various sectors, particularly in the Health Services and Health Care Benefits segments.

Financial Highlights

During the third quarter, CVS Health reported a diluted earnings per share (EPS) of $1.68 under Generally Accepted Accounting Principles (GAAP) and an adjusted EPS of $2.09. The GAAP diluted EPS saw a robust turnaround compared to a loss per share of $3.13 recorded in the previous year, as the latter was significantly impacted by a $5.7 billion goodwill impairment charge in 2025. Remarkably, the adjusted EPS reflected an increase from $1.60 in the prior year, driven by improved operating margins in the Health Care Benefits segment.

Year-to-date, the company generated $15.3 billion in cash flow from operations, signaling solid operational performance. CVS has revised its full-year guidance upwards, now projecting a GAAP diluted EPS of at least $6.98 and an adjusted EPS of at least $8.20, alongside cash flow guidance of at least $15.5 billion.

Segment Performance

Breaking down the performance of its business segments, the Health Care Benefits segment saw a total revenue increase of 2.4% for the third quarter, amounting to $36.9 billion. The growth has been largely driven by its Government business, despite witnessing some decline in its commercial offerings due to exiting the individual exchange business. The Adjusted operating income for this segment rose significantly, showcasing improved performance metrics with a medical benefit ratio of 91.3%, down from 92.8% in 2025.

On the Health Services front, CVS Health's revenue surged by 9.5% to $54.0 billion, primarily boosted by favorable pharmacy drug mix and inflation in brand drugs. The segment reported adjusted operating income increases thanks to improved purchasing economics, with pharmacy claims processed also seeing a mild rise.

Lastly, the Pharmacy Consumer Wellness segment faced a slight revenue drop of 2.0%, impacted by regulatory price reductions on specific drugs. However, adjusted operating income grew by 10.6%, highlighting core pharmacy strength and contributions from Rite Aid asset acquisitions.

Commitment to Quality Care

CVS Health's dedication to enhancing the consumer experience continues to ground its operational strategy. Over 69% of Aetna’s Medicare Advantage members are enrolled in 2027 plans rated four stars or higher, affirming the company’s role as a trustworthy provider in the Medicare landscape. This year marks the third consecutive year where Aetna has shown commendable performance across various clinical quality and preventive care metrics.

CVS Health also remains at the forefront of integrated health services, offering direct-to-consumer weight management solutions to improve access and support for GLP-1 medications through its network of pharmacies. This includes in-person and virtual support, ensuring that consumers have comprehensive health management resources at their fingertips.

Conclusion

As CVS Health marks a successful third quarter in 2026, the company’s efforts towards improving health outcomes while lowering costs reflect its mission to simplify health care. Enhanced guidance for the remainder of the year further encourages confidence in CVS Health's strategic direction. With a robust operational model in place, the company aims to provide better health outcomes for individuals and communities alike, marking its significance as a key player in the health solutions sector.